{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-000700","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.811878+00:00","generated_at":"2026-05-25T11:45:53.834486+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion Therapeutics reports positive initial data from SIL204 in orthotopic pancreatic cancer models","bullets":["SIL204 reduced primary tumor bioluminescence by ~70% in AsPC-1 (KRAS G12D) and ~80% in BxPC-3 (wild-type) models by day 28.","In Panc-1 model, SIL204 decreased bioluminescence by 12% vs. baseline while control increased >100% (p<0.05) by day 14.","Subcutaneous SIL204 significantly reduced metastatic spread to liver, intestine, spleen, and stomach in Panc-1 and BxPC-3 models.","Data provide initial validation of systemic delivery efficacy for treating both primary tumors and metastases in orthotopic models.","Company plans to provide updated development strategy leveraging systemic administration approach in coming weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-000700","json":"https://secwatch.observer/filing/0001178913-25-000700.json","markdown":"https://secwatch.observer/filing/0001178913-25-000700.md","text":"https://secwatch.observer/filing/0001178913-25-000700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000700/0001178913-25-000700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000700/zk2532812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-25T11:45:53.834486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}